ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ASH 2024 Summary: FL Highlights

2024 ASH Annual Meeting Insights Hub

P. Strati

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Standards of Care and Future Directions in FL

Martin Dreyling

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

ASH 2025 Review: Key Trials and Takeaways in 1L and R/R Follicular L…

University of Colorado Division of Hematology

T. Phillips

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Tandem 2025 Insights: Clinical Practice Recommendations for HCT and …

Insights from 2025 Tandem Annual Meeting

M. Iqbal

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Tazemetostat in Older Frail Adults With Follicular Lymphoma

Erin Mulvey

ASH 2024 Summary: The POD24 Challenge in FL - Where Do We Go From He…

2024 ASH Annual Meeting Insights Hub

C. Casulo

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

What's Current in Immunotherapy in DLBCL and FL

Houston Methodist

A. Mehta